

AD \_\_\_\_\_

GRANT NO:  
DAMD17-94-J-4048


**TITLE:**

Rotational Resonance NMR Structural Studies of the neu Receptor  
Transmembrane Domain

**PRINCIPAL INVESTIGATOR:**  
Steven O. Smith, Ph.D.

**CONTRACTING ORGANIZATION:**  
Yale University  
New Haven, Connticut 06520-8114

**REPORT DATE:**  
23 May 95



**TYPE OF REPORT:**

Annual

**PREPARED FOR:** U.S. Army Medical Research and Materiel  
Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19950703 037

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                             |                                                            |                                         |                                                              |  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|------------------------------------------------------------|-----------------------------------------|--------------------------------------------------------------|--|
| 1. AGENCY USE ONLY (Leave blank)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                             | 2. REPORT DATE<br>23May95                                  |                                         | 3. REPORT TYPE AND DATES COVERED<br>Annual 23May94 - 23May95 |  |
| 4. TITLE AND SUBTITLE<br>Rotational resonance NMR structural studies of the neu receptor transmembrane domain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                             |                                                            |                                         | 5. FUNDING NUMBERS<br>DAMD-17-94-J-4048                      |  |
| 6. AUTHOR(S)<br>Steven O. Smith                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                             |                                                            |                                         |                                                              |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br>Yale University<br>P.O. Box 208047<br>333 Cedar Street<br>New Haven, CT 06520-8047                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                             |                                                            |                                         | 8. PERFORMING ORGANIZATION<br>REPORT NUMBER                  |  |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                             |                                                            |                                         | 10. SPONSORING/MONITORING<br>AGENCY REPORT NUMBER            |  |
| 11. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                             |                                                            |                                         |                                                              |  |
| 12a. DISTRIBUTION/AVAILABILITY STATEMENT<br><br>Approved for public release, distribution unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                             |                                                            |                                         | 12b. DISTRIBUTION CODE                                       |  |
| 13. ABSTRACT (Maximum 200 words)<br><br>In order to determine the structure of the transmembrane domain of the neu/erbB-2 receptor and address the molecular mechanism of receptor activation by the transforming V <sub>664</sub> to E <sub>664</sub> mutation, magic angle spinning NMR and polarized Fourier transform infrared studies have been undertaken. These studies show that the region C-terminal to position 664 is helical and oriented roughly perpendicular to the membrane plane. When the E <sub>664</sub> carboxyl group is deprotonated, the region N-terminal to position 664 unfolds and the COO- group is exposed to the polar membrane interface. Protonation allows the peptide to adopt a helical conformation oriented perpendicular to the membrane plane. The pK <sub>a</sub> of the E <sub>664</sub> side chain is shifted by the membrane surface charge. Under conditions approximating those in native membranes, the carboxyl group readily partitions into the membrane. The high pK <sub>a</sub> observed for the E <sub>664</sub> carboxyl group and increased orientation in DMPC:DMPS membranes argues that the V <sub>664</sub> to E <sub>664</sub> mutation causes the transmembrane domain to dimerize.<br><br>DTIC QUALITY INSPECTED 3 |                                                             |                                                            |                                         |                                                              |  |
| 14. SUBJECT TERMS<br>nev/erbB-2 receptor, NMR, structure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                             |                                                            |                                         | 15. NUMBER OF PAGES<br>13                                    |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                             |                                                            |                                         | 16. PRICE CODE                                               |  |
| 17. SECURITY CLASSIFICATION<br>OF REPORT<br>Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18. SECURITY CLASSIFICATION<br>OF THIS PAGE<br>Unclassified | 19. SECURITY CLASSIFICATION<br>OF ABSTRACT<br>Unclassified | 20. LIMITATION OF ABSTRACT<br>Unlimited |                                                              |  |

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

( ) Where copyrighted material is quoted, permission has been obtained to use such material.

( ) Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

(\*) Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

( ) In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

( ) For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 32 CFR 219 and 45 CFR 46.

( ) In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

  
Principal Investigator's Signature

5/22/95  
Date

|                      |                                     |
|----------------------|-------------------------------------|
| <b>Accession For</b> |                                     |
| NTIS GRA&I           | <input checked="" type="checkbox"/> |
| DTIC TAB             | <input type="checkbox"/>            |
| Unannounced          | <input type="checkbox"/>            |
| Justification        |                                     |
| By                   |                                     |
| Distribution/Avail   |                                     |
| Availability Codes   |                                     |
| Dist                 | Avail and/or Special                |
| A-1                  |                                     |

## TABLE OF CONTENTS

### Rotational Resonance NMR Structural Studies of the neu Receptor Transmembrane Domain

|              |   |
|--------------|---|
| Introduction | 2 |
| Body         | 4 |
| Conclusions  | 8 |
| References   | 9 |

## INTRODUCTION

The neu/erbB-2 receptor has two cysteine-rich extracellular domains, a single helical membrane-spanning domain and an intracellular tyrosine kinase domain [1-4]. A single mutation (V664E) within the hydrophobic transmembrane sequence leads to constitutive activation of the receptor.

Two models have been proposed for how the V<sub>664</sub> → E<sub>664</sub> substitution causes cell transformation. The first involves a change in the secondary structure of the TM domain. Brandt-Rauf et al. (1990) [5] calculated that the minimum-energy conformation in the region of V<sub>664</sub> contains a sharp bend at positions 664 and 665, while the transforming sequence exists as an  $\alpha$ -helix. The second model is that the glutamate side chain promotes dimerization via hydrogen-bonding interactions [6]. In this case, the helices are thought to be held in the "active" state by hydrogen bonding between the E<sub>664</sub> carboxylic acid side chain on one helix and the E<sub>664</sub> side chain or peptide backbone C=O/NH groups of the second helix. Consistent with this model, the transforming (E<sub>664</sub>) protein has a higher propensity to form dimers than the normal (V<sub>664</sub>) protein [7]. The position of the glutamic acid residue is sequence specific. Bargmann and Weinberg originally demonstrated that substitution of glutamic acid at positions 663 or 665 did not activate the receptor [1].

Stern and coworkers have undertaken an extensive mutagenesis study of the *neu* TM domain to define the residues that are responsible for receptor activation [4]. They found that a sub-domain, -V<sub>663</sub>-E<sub>664</sub>-G<sub>665</sub>-, is important. The domain differs slightly from that predicted by Sternberg and Gullick [6], most notably in the importance of A<sub>661</sub> for receptor dimerization. Gullick and coworkers [8] have shown that intracellular expression of small proteins, corresponding to the TM and membrane-proximal domains of neu and containing variations on the activated neu TM sequence, inhibits growth of neu transformed cells. However, a simple model involving hydrogen-bonding interactions of the E<sub>664</sub> may not be sufficient to explain receptor activation. Stern and coworkers [4] have shown, by moving the VEG sub-domain around in the TM sequence and by generating mutants that dimerize without activating the receptor, that dimerization alone is insufficient to cause cell transformation and that the interactions are likely to be highly specific. No direct evidence has been obtained for the points of contact in the receptor dimers and a high-resolution structure is needed to determine the exact nature of the protein interactions and whether they are distributed along the length of the TM domain.

In order to determine the structure of the transmembrane domain of the neu/erbB-2 receptor and address the molecular mechanism of receptor activation by the transforming V<sub>664</sub> to E<sub>664</sub> mutation, magic angle spinning (MAS) NMR and polarized Fourier transform infrared (FTIR) studies have been undertaken. We have previously shown that MAS NMR and FTIR measurements provide a feasible approach for structural studies on membrane proteins [9-11].

MAS yields high resolution NMR spectra of membrane proteins in bilayer environments [6] and several different strategies have been developed for measuring weak dipolar couplings in MAS experiments [12-15]. Of importance for structural studies is that accurate internuclear distances can be derived from measurements of dipolar couplings which in turn provide constraints for generating and evaluating structural models. The two best established approaches are rotational resonance (RR) and rotational echo double resonance (REDOR) NMR. The RR NMR approach selectively restores the dipolar couplings by spinning the sample such that an integral multiple of the MAS frequency is

equal to the chemical shift difference ( $\Delta\omega$ ) between two NMR resonances [16-18]. The distance limits for  $^{13}\text{C}\dots^{13}\text{C}$  measurements using RR NMR is  $\sim 6.5 \text{ \AA}$  with resolution on the order of  $0.3 \text{ \AA}$ . The REDOR NMR approach has been developed to measure weak heteronuclear dipolar couplings, such as those between  $^{31}\text{P}$  and  $^{13}\text{C}$  or  $^{15}\text{N}$  and  $^{13}\text{C}$  [19,20]. REDOR relies on the dephasing of magnetization of the observed spin through coupling to a second spin. The distance limit for  $^{13}\text{C}\dots^{15}\text{N}$  measurements using REDOR NMR is  $\sim 5 \text{ \AA}$  with resolution on the order of  $0.2 \text{ \AA}$ .

The global secondary structure and orientation of membrane proteins and peptides can be probed by polarized FTIR spectroscopy using the amide I vibration as a structurally sensitive marker [21]. The frequency of the amide I mode depends on hydrogen-bonding of the C=O group as well as on the geometry of the peptide backbone. Bands centered at  $\sim 1654 \text{ cm}^{-1}$  correspond to  $\alpha$ -helical structures, while bands centered at  $1624 - 1637 \text{ cm}^{-1}$  and  $1675 \text{ cm}^{-1}$  correspond to the out-of-phase and in-phase modes of  $\beta$ -sheet structures, respectively or alternatively  $\beta$ -turn. Fourier self deconvolution (FSD) of the amide I region [22] can yield quantitative estimates of the relative ratios between the different secondary structural elements of the protein [23]. The orientation of C=O group, which dominates the amide I vibration, can be derived from the relative absorption of IR light polarized parallel or perpendicular to the C=O transition dipole moment. Maximum absorption occurs when the polarization of light is parallel to the transition moment. In an  $\alpha$ -helix, the C=O transition dipole is known to be oriented at an angle of  $\sim 39^\circ$  relative to the helix axis [24-26].

Using both MAS NMR and FTIR, we have shown that peptides 38 residues in length that incorporate the transmembrane domain of the activated receptor (neu\*TM) form extended helical structures oriented perpendicular to the membrane surface. Furthermore, the  $\text{pK}_a$  of the E<sub>664</sub> carboxyl group in membranes is considerably higher than that of free glutamate indicating the E<sub>664</sub> carboxyl group is buried in the membrane interior, possibly in the dimer interface between TM domains.

## BODY

Figure 1 (left) presents the Fourier self deconvolutions of polarized ATR-FTIR spectra of neu\*TM incorporated into DMPC bilayers. The spectra were obtained with parallel (solid lines) and perpendicular (dashed lines) polarized light as described in [16]. The amide I band is centered at  $1655\text{ cm}^{-1}$ , characteristic of helical secondary structure. Increasing the pH from pH 5.5 to pH 7.0 results in a substantial increase in a band at  $1630\text{ cm}^{-1}$  that may be attributed to extended  $\beta$ -structure. The orientation of the helical region of the peptide is estimated from the dichroic ratio ( $I_{\text{parallel}}/I_{\text{perpendicular}}$ ) of the amide I band at  $1655\text{ cm}^{-1}$ . The measured dichroic ratio at pH 5.5 corresponds to a helix angle of  $25^\circ$  relative to the bilayer normal. The orientation is roughly the same at pH 8.5.

The neu\*TM peptides were synthesized using solid-phase methods at the Keck Peptide Synthesis Facility at Yale University. The sequence of the 38-residue peptide corresponds to residues 649-686 in the human neu receptor protein.

AEQRASPVTFILATV-E664-GVLLFLALVVVVGILIKRRRYK

The lyophilized peptide was dissolved in trifluoroacetic acid and purified using a 5 ml POROS-R1 reverse phase high performance liquid chromatography (RP-HPLC) column (Perceptive Biosystems, Cambridge, MA) equilibrated with 95%  $\text{H}_2\text{O}$ , 2% acetonitrile and 3% 2-propanol. Peptide elution was achieved with a linear gradient to a final solvent composition of 5%  $\text{H}_2\text{O}$ , 38% acetonitrile and 57% 2-propanol. All solvents contained 0.1% trifluoroacetic acid. Fractions containing peptides were then lyophilized and assessed for purity by amino acid analysis (correlation coefficients of  $> 0.95$ ) and mass spectrometry.

Peptide fractions were lyophilized and reconstituted into lipids as follows. Peptide and lipids were codissolved at a 30:1 molar ratio with 2% n-octyl  $\beta$ -glucopyranoside (Sigma, St. Louis, MO) in trifluoroethanol. Lipids (Avanti Polar Lipids, Alabaster, AL) used were dimyristoyl phosphatidylcholine (DMPC) and dimyristoyl phosphatidylserine (DMPS) (14% by weight). Samples were dried with nitrogen gas and resolubilized in 6 ml of dialysis buffer [0.5 mM sodium azide, 0.5 mM HEPES, pH 7.0]. Samples were split into three dialysis groups for each pH. One of each lipid sample was placed into each of the following buffers: 1 mM MES, 0.5 mM sodium azide, pH 5.5; 1mM HEPES, 0.5 mM sodium azide, pH 7.0; and 1 mM TAPS, 0.5 mM sodium azide, pH 8.5; and dialysed overnight. 300  $\mu\text{l}$  of each sample were allocated for ATR-FTIR, approximately 100  $\mu\text{l}$  used for transmission IR, and the remaining pelleted and prepared for MAS-NMR experiments.

FTIR spectra were recorded on a Nicolet Magna 550 spectrometer purged with  $\text{N}_2$  (Madison, WI) and equipped with a MCT/A detector. For transmission spectra, typically 50  $\mu\text{l}$  of sample (protein concentration of 36 - 90 mM) is dried on AgCl windows with dry air. For polarized ATR-FTIR spectra, the spectrometer is equipped with a KRS-5 wire grid polarizer (0.25 mm spacing, Grasbey Specac, Kent, UK). The sample ( $\sim 300\text{ }\mu\text{l}$ , 36 - 90 mM) is dried on the surface of a Ge internal reflection element and placed in a variable angle ATR accessory (Grasbey Specac, Kent, UK). Fourier self deconvolution spectra [FSD, 22] were obtained using a bandwidth of  $13\text{ cm}^{-1}$  and an enhancement factor of 2.4, determined by Byler and Susi [23] to best fit experimental data. The helical content and orientation was determined using the approach described in our recent work on phospholamban [9].




Figure 1: (Left) Polarized FTIR spectra of the amide I band of neu\*TM in DMPC multilayers. Fourier self deconvolutions are shown of spectra obtained of oriented membranes at pH 5.5 (a) pH 7.0 (b) and pH 8.5 (c). Spectra were obtained with parallel (solid) and perpendicularly (dashed) polarized light.

(Right) Polarized FTIR spectra of the amide I band of neu\*TM in DMPC:DMPS multilayers. Fourier self deconvolutions are shown of spectra obtained of oriented membranes at pH 5.5 (d) pH 7.0 (e) and pH 8.5 (f). Spectra were obtained with parallel (solid) and perpendicularly (dashed) polarized light.



The most straightforward interpretation of the FTIR data is that increasing the pH results in local unfolding of the peptide. The current hypothesis is that protonation of E<sub>664</sub> allows the peptide to fold into a long  $\alpha$ -helix spanning the membrane stretching from the C-terminus through position 664. Deprotonation is thought to lead to unfolding of the helix from E<sub>664</sub> to the N-terminus of the protein. This suggests that E<sub>664</sub> titrates with a pK<sub>a</sub> between 5.5 and 7. This is a substantial increase over the 4 - 4.5 solution pK<sub>a</sub> of glutamic acid. However, an increased pK<sub>a</sub> might be expected to result from the surface charge on DMPC bilayers. Previous studies on membrane lipids and fatty acids have shown that the apparent pK<sub>a</sub> increases near the membrane surface [28-30]. The apparent pK<sub>a</sub> corresponds to the bulk pH at which half of the COOH groups are protonated, and should be distinguished from the intrinsic pK<sub>a</sub> which corresponds to the surface pH at which half of the COOH groups are protonated.

In order to determine whether the E<sub>664</sub> side chain titrates with a pK<sub>a</sub> between 5.5 and 7.0, MAS NMR spectra were obtained of neu\*TM labeled with [5-<sup>13</sup>C] glutamate reconstituted into DMPC bilayers. The <sup>13</sup>C chemical shift of the E<sub>664</sub> carboxyl group is sensitive to its protonation state with the isotropic chemical shift moving downfield upon deprotonation [27].

Figure 2 presents MAS NMR spectra of the neu\*TM domain in DMPC bilayers at pH 5.5 (a), pH 7.0 (b) and pH 8.5 (c). In Figure 2a, the resonance at 179.6 ppm is assigned to the side chain carboxyl of E<sub>664</sub> based on a comparison with unlabeled peptide. Increasing the pH to 7.0 (Figure 2b) results in the appearance of a second resonance at 180.9 ppm. The intensity of the 180.9 ppm resonance increases in intensity when the pH is further increased to 8.5 (Figure 2c). Integration of the intensities of a full pH series from pH 5.5 to 8.5 indicates that the apparent pK<sub>a</sub> of E<sub>664</sub> in DMPC bilayers is ~6.5. Again, this is a substantial increase over the 4 - 4.5 solution pK<sub>a</sub> of glutamic acid.




Figure 2: MAS NMR spectra of neu\*TM at pH 5.5 (a), 7.0 (b) and 8.5 (c) in DMPC multilayers. Spectra were obtained at a <sup>13</sup>C frequency of 90.4 MHz with a MAS speed of 5.000 kHz. The spectra shown are actually difference spectra where a spectrum of unlabeled neu reconstituted in DMPC has been subtracted. The temperature was maintained at -20°C. At higher temperatures, the two resonances broaden and collapse into a single line due to exchange.

In order to establish how membrane surface charge influences the pKa of the E664, we incorporated 14% DMPS into the DMPC vesicles. DMPS is the major negatively charged lipid in mammalian cell membranes and usually ranges in concentration from 10 - 20%. The FSDs of the amide I band of neu\*TM in DMPC:DMPS membranes are shown in Figure 1 (d-f). The frequency and intensity of the FSD band at  $1655\text{ cm}^{-1}$  argue that the peptide is predominantly helical. The orientation is significantly more transmembrane than in DMPC vesicles.

Figure 3 presents a model that incorporates the results described above. First, the region C-terminal to position 664 is helical and oriented roughly perpendicular to the membrane plane. When the E664 carboxyl group is deprotonated, the region N-terminal to position 664 unfolds and the COO<sup>-</sup> group is exposed to the polar membrane interface. Protonation allows the peptide to adopt a helical conformation oriented perpendicular to the membrane plane. The pKa of the E664 side chain is shifted by the membrane surface charge. Under conditions approximating those in native membranes, the carboxyl group readily partitions into the membrane. The high pKa observed for the E664 carboxyl group and increased orientation in DMPC:DMPS membranes may reflect dimerization of the peptides in membranes.




Figure 3: Model illustrating the influence of membrane surface potential on the pKa of E664 in neu\*TM.

## CONCLUSIONS

In general, hydrogen-bonding interactions between amino acid side chains or between side chains and the helix backbone promise to be a major mechanism for gaining specificity in dimer formation. The results on neu\*TM described above set the stage for studying hydrogen-bonding interactions neu\*TM helices. We have shown that the neu\*TM peptides form extended helical structures oriented perpendicular to the membrane surface. Furthermore, the high pKa of the COOH group in neu\*TM reconstituted into DMPC:DMPS membranes indicate that the E664 carboxyl group is buried in the membrane interior, possibly in the dimer interface between TM domains.

The experimental plan is to test two models for hydrogen-bonding interactions in the dimer interface of neu\*TM (Figure 4). We plan to study both glutamic acid and glutamine at position 664. Both substitutions are known to activate the receptor. Studies on glutamine have an advantage in that heteronuclear experiments can be designed using  $^{15}\text{N}$  and  $^{13}\text{C}$  labels. The transmembrane peptides containing glutamine are also not sensitive to the membrane surface charge. This removes surface charge as a variable in characterizing dimer structure. The first model involves side chain - side chain hydrogen bonding interactions as the mechanism for receptor dimerization. The second model involves backbone - side chain interactions.




Figure 4: Models for neu\*TM dimerization. In (a), dimerization is mediated by hydrogen-bonding interactions between the polar side chains of glutamine residues. In (b), dimerization is mediated by hydrogen-bonding interactions between backbone carbonyls and the polar side chain of glutamine.

## REFERENCES

- 1 Bargmann CI, Weinberg RA. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. *EMBO J* 1988; 7:2043-2052.
- 2 Bargmann CI, Hung M-C, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. *Cell* 1986; 45:649-657.
- 3 Bargmann CI, Hung M-C, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. *Nature* 1986; 319:226-230.
- 4 Cao H, Bangalore L, Bormann B-J, Stern DF. A subdomain in the transmembrane domain is necessary for p185neu\* activation. *EMBO J* 1992; 11:923-932.
- 5 Brandt-Rauf PW, Rackovsky S, Pincus MR. Correlation of the structure of the transmembrane domain of the neu oncogene-encoded p185 protein with its function. *Proc Natl Acad Sci U S A* 1990; 87:8660-8664.
- 6 Sternberg MJ, Gullick WJ. Neu receptor dimerization. *Nature* 1989; 339:587.
- 7 Weiner DB, Liu J, Cohen FA, Williams WV, Greene MI. *Nature* 1989; 339:230-231.
- 8 Lofts FJ, Hurst HC, Sternberg MJE, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. *Oncogene* 1993; 8:2813-2820.
- 9 Arkin IT, Rothman M, Ludlam CFC, Aimoto S, Engelman DE, Rothschild K, Smith SO. Structural model of the phospholamban ion channel complex in phospholipid membranes. *J Mol Biol* 1995; 248:824-834.
- 10 Smith SO, Jonas R, Braiman M, Bormann BJ. Structure and orientation of the transmembrane domain of glycophorin A in lipid bilayers. *Biochemistry* 1994; 33:6334-6341.
- 11 Smith SO, Bormann BJ. Determination of helix-helix interactions in membranes by rotational resonance NMR. *Proc Natl Acad Sci USA* 1995; 92:488-491.
- 12 Levitt MH, Raleigh DP, Creuzet F, Griffin RG. Theory and simulations of homonuclear spin pair systems in rotating solids. *J Chem Phys* 1990; 92:6347.
- 13 Gullion T, Schaefer J. Detection of weak heteronuclear dipolar coupling by rotational echo double-resonance nuclear magnetic resonance. *Adv Magn Reson* 1989; 13:57-83.
- 14 Hing AW, Vega S, Schaefer J. Transferred-echo double resonance NMR. *J Magn Reson* 1992; 96:205-209.
- 15 Tycko R, Smith SO. Symmetry principles in the design of pulse sequences for structural measurements in magic angle spinning nuclear magnetic resonance. *J Chem Phys* 1993; 98:932-943.

- 16 Colombo MG, Meier BH, Ernst RR. Rotor-driven spin diffusion in natural-abundance  $^{13}\text{C}$  Spin Systems. *Chem Phys Lett* 1988; 146:189-196.
- 17 Peersen OB, Yoshimura S, Hojo H, Aimoto S, Smith SO. Short range distance determination in integral membrane proteins by magic angle spinning NMR. *J Am Chem Soc* 1992; 114:4332-4335.
- 18 Peersen OB, Smith SO. Rotational resonance NMR of biological membranes. *Concepts in Magn Reson* 1993; 5:305-317.
- 19 Bork V, Gullion T, Hing A, Schaefer J. Measurement of  $^{13}\text{C}$  -  $^{15}\text{N}$  coupling by dipolar-rotational spin-echo NMR. *J Magn Reson* 1990; 88:523-532.
- 20 Gullion T, Schaefer J. Rotational-Echo Double-Resonance NMR. *J Magn Reson* 1988; 81:196-200.
- 21 Braiman MS, Rothschild KJ. Fourier transform infrared techniques for probing membrane protein structure. *Ann Rev Biophys Biophys Chem* 1989; 17:541-570.
- 22 Kauppinen JK, Moffatt DJ, Mantsch HH, Cameron DG. Fourier self-deconvolution: A method for resolving intrinsically overlapped bands. *Appl Spectrosc* 1981; 35:271-276.
- 23 Byler MD, Susi H. Examination of the secondary structure of proteins by Deconvolved FTIR spectra. *Biopolymers* 1986; 25:469-487.
- 24 Bradbury EM, Brown L, Downie AR, Elliott A, Fraser RDB, Hanby WE. The structure of the  $\omega$ -form of poly- $\beta$ -benzyl-L-aspartate. *J Mol Biol* 1962; 5:230-247.
- 25 Miyazawa T, Blout ER. The infrared spectra of polypeptides in various conformations: amide I and amide II bands. *J Am Chem Soc* 1961; 83:712-719.
- 26 Tsuboi M. Infrared dichroism and molecular conformation of  $\alpha$ -form poly- $\gamma$ -benzyl-L-glutamate. *J Polymer Sci* 1994; 59:139-153.
- 27 Gu Z, Zambrano R, McDermott A. Hydrogen bonding of carboxyl groups in solid-state amino acids and peptides: comparison of carbon chemical shielding, infrared frequencies, and structures. *J Am Chem Soc* 1994; 116:6368-6372.
- 28 Hamilton JA, Cistola DP. Transfer of oleic acid between albumin and phospholipid vesicles. *Proc Natl Acad Sci USA* 1986; 83:82-86.
- 29 Kantor HL, Prestegard JP. Fusion of phosphatidylcholine bilayer vesicles: role of free fatty acid. *Biochemistry* 1978; 17:3592-3597.
- 30 Ptak M, Egret-Charlier M, Sanson A, Bouloussa O. A NMR study of the ionization of fatty acids, fatty amines and N-acylamino acids incorporated in phosphatidylcholine vesicles. *Biochim Biophys Acta* 1980; 600:387-397.